Table 3 CircN4BP2L2, CA125 and HE4 expression levels according to histology, type and stage; ROC AUC, sensitivity, specificity, and significant difference in type I EOC vs. benign and normal cohorts

Median (range)

Median (range)

ROC AUC

(95% CI)

Sen

Spe

P-value

Median (range)

ROC AUC

(95% CI)

Sen

Spe

P-value

CircN4BP2L2

21 (7–95)

82 (1–367)

0.84 (0.79–0.89)

69%

87%

< 0.01^*

82 (11–439)

0.87 (0.82–0.92)

69%

93%

< 0.01^*

 Early-stage ^a

25 (7–91)

0.79 (0.72–0.85)

90%

56%

< 0.01^*

0.81 (0.75–0.88)

55%

93%

< 0.01^*

 Late-stage ^a

15 (11–95)

0.92 (0.86–0.97)

87%

94%

< 0.01^*

0.95 (0.90–0.99)

87%

98%

< 0.01^*

CA125

85 (16–5420)

48 (13–373)

0.55 (0.46–0.65)

59%

32%

0.20

29 (4–69)

0.73 (0.65–0.81)

59%

58%

< 0.01^*

 Early-stage ^a

33 (16–181)

0.40 (0.30–0.51)

48%

32%

0.06

0.64 (0.53–0.75)

48%

58%

< 0.01^*

 Late-stage ^a

506 (18–5420)

0.75 (0.62–0.88)

73%

32%

< 0.01^*

0.85 (0.75–0.94)

73%

58%

< 0.01^*

HE4

61 (28–298)

46 (12–237)

0.70 (0.63–0.76)

54%

76%

< 0.01^*

44 (7–235)

0.70 (0.63–0.77)

54%

82%

< 0.01^*

 Early-stage ^a

50 (28–207)

0.62 (0.53–0.70)

38%

76%

0.02^*

0.63 (0.54–0.71)

38%

82%

0.01^*

 Late-stage ^a

69 (43–298)

0.80 (0.73–0.87)

77%

76%

< 0.01^*

0.80 (0.74–0.87)

77%

82%

< 0.01^*